Cardiac function may be compromised in patients with elevated blood cobalt levels secondary to metal-on-metal hip implants : a pilot study using a novel echocardiography measurement

Tools

Jenkinson, Mark R. J. and Meek, Dominic R. M. and Tate, Rothwelle and Brady, Adrian and MacMillan, Sandy and Grant, Helen and Currie, Susan (2024) Cardiac function may be compromised in patients with elevated blood cobalt levels secondary to metal-on-metal hip implants : a pilot study using a novel echocardiography measurement. The Bone & Joint Journal, 106-B (No.3 S). pp. 51-58. ISSN 2049-4394 (https://doi.org/10.1302/0301-620X.106B3.BJJ-2023-0...)

[thumbnail of Jenkinson-etal-BJJ-2024-Cardiac-function-may-be-compromised] Text. Filename: Jenkinson-etal-BJJ-2024-Cardiac-function-may-be-compromised.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 1 March 2025.
License: Strathprints license 1.0
Download (800kB) | Request a copy

Abstract

Aims: Elevated blood cobalt levels secondary to metal-on-metal (MoM) hip arthroplasties are a suggested risk factor for developing cardiovascular complications including cardiomyopathy. Clinical studies assessing patients with MoM hips using left ventricular ejection fraction (LVEF) have found conflicting evidence of cobalt-induced cardiomyopathy. Global longitudinal strain (GLS) is an echocardiography measurement known to be more sensitive than LVEF when diagnosing early cardiomyopathies. The extent of cardiovascular injury, as measured by GLS, in patients with elevated blood cobalt levels has not previously been examined. Methods: A total of 16 patients with documented blood cobalt ion levels above 13 µg/l (13 ppb, 221 nmol/l) were identified from a regional arthroplasty database. They were matched with eight patients awaiting hip arthroplasty. All patients underwent echocardiography, including GLS, investigating potential signs of cardiomyopathy. Results: Patients with MoM hip arthroplasties had a mean blood cobalt level of 29 µg/l (495 nmol/l) compared to 0.01 µg/l (0.2 nmol/l) in the control group. GLS readings were available for seven of the MoM cohort, and were significantly lower when compared with controls (-15.5% vs -18% (MoM vs control); p = 0.025)). Pearson correlation demonstrated that GLS significantly correlated with blood cobalt level (r = 0.8521; p < 0.001). However, there were no differences or correlations for other echocardiography measurements, including LVEF (64.3% vs 63.7% (MoM vs control); p = 0.845). Conclusion: This study supports the hypothesis that patients with elevated blood cobalt levels above 13 µg/l in the presence of a MoM hip implant may have impaired cardiac function compared to a control group of patients awaiting hip arthroplasty. It is the first study to use the more sensitive parameter of GLS to assess for any cardiac contractile dysfunction in patients with a MoM hip implant and a normal LVEF. Larger studies should be performed to determine the potential of GLS as a predictor of cardiac complications in patients with MoM arthroplasties.

ORCID iDs

Jenkinson, Mark R. J., Meek, Dominic R. M., Tate, Rothwelle, Brady, Adrian, MacMillan, Sandy, Grant, Helen ORCID logoORCID: https://orcid.org/0000-0002-7712-404X and Currie, Susan ORCID logoORCID: https://orcid.org/0000-0002-4237-4428;
CORE (COnnecting REpositories)